Edition:
United Kingdom

Regulus Therapeutics Inc (RGLS.OQ)

RGLS.OQ on NASDAQ Stock Exchange Global Market

0.90USD
14 Dec 2017
Change (% chg)

-- (--)
Prev Close
$0.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
118,491
52-wk High
$2.75
52-wk Low
$0.79

Chart for

About

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return... (more)

Overall

Beta: 1.65
Market Cap(Mil.): $142.19
Shares Outstanding(Mil.): 103.79
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.65 16.44
EPS (TTM): -- -- --
ROI: -- 2.35 10.62
ROE: -- 2.95 14.20

BRIEF-Regulus Therapeutics Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events

08 Nov 2017

BRIEF-Regulus Q3 loss per share $0.18

* Regulus reports third quarter 2017 financial results and recent events

07 Nov 2017

BRIEF-Growth Equity Opportunities reports 11.3 pct stake in Regulus Therapeutics

* Growth Equity Opportunities V reports 11.3 percent stake in Regulus Therapeutics Inc as of July 24 - SEC filing Source text: (http://bit.ly/2u4yxoS) Further company coverage:

02 Aug 2017

BRIEF-Regulus Therapeutics Q2 loss per share $0.41

* Regulus reports second quarter 2017 financial results and recent events

01 Aug 2017

BRIEF-Broadfin Capital reports 5.65 pct passive stake in Regulus Therapeutics - ‍​SEC filing

* Broadfin Capital LLC reports 5.65 percent passive stake in Regulus Therapeutics Inc as of July 20, 2017 - ‍​SEC filing Source text: (http://bit.ly/2vSFqWv) Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)

24 Jul 2017

Competitors

Earnings vs. Estimates